Claims for Patent: 8,119,123

Summary for Patent: 8,119,123

Title:	Compositions comprising vascular and myocyte progenitor cells and methods of their use
Abstract:	The invention provides compositions of adult cardiac vascular progenitor cells (VPCs) and adult cardiac myocyte progenitor cells (MPCs) useful for the treatment of various cardiac conditions. The invention also encompasses methods of generating a biological bypass, repairing damaged myocardium, and treating or preventing hypertensive cardiomyopathy and heart failure with the compositions of the invention. Methods of isolating the cardiac progenitor cells are also disclosed.
Inventor(s):	Anversa; Piero (Boston, MA), Leri; Annarosa (Boston, MA), Kajstura; Jan (Brookline, MA)
Assignee:	New York Medical College (Valhalla, NY)
Application Number:	12/325,776
Patent Claims:	1. A pharmaceutical composition consisting of isolated adult vascular progenitor cells and a pharmaceutically acceptable carrier, wherein the vascular progenitor cells are lineage negative, c-kit positive, VEGFR-2 positive, and CD34 negative. 2. The pharmaceutical composition of claim 1, wherein said vascular progenitor cells are isolated from human myocardium or human myocardial vessels. 3. The pharmaceutical composition of claim 1, wherein said vascular progenitor cells are clonogenic and at least 80% of the cells generated from said vascular progenitor cells are endothelial cells and smooth muscle cells. 4. The pharmaceutical composition of claim 1, wherein the concentration of vascular progenitor cells is about 1.times.10.sup.5 cells/ml to about 1.times.10.sup.7 cells/ml. 5. A pharmaceutical composition consisting of isolated adult myocyte progenitor cells and a pharmaceutically acceptable carrier, wherein the myocyte progenitor cells are lineage negative, c-kit positive, VEGFR-2 negative, and CD34 negative. 6. The pharmaceutical composition of claim 5, wherein said myocyte progenitor cells are isolated from human myocardium. 7. The pharmaceutical composition of claim 5, wherein said myocyte progenitor cells are clonogenic and at least 80% of the cells generated from said myocyte progenitor cells are cardiomyocytes. 8. The pharmaceutical composition of claim 5, wherein the concentration of myocyte progenitor cells is about 1.times.10.sup.5 cells/ml to about 1.times.10.sup.7 cells/ml. 9. The pharmaceutical composition of claim 1, wherein said vascular progenitor cells are autologous. 10. The pharmaceutical composition of claim 5, wherein said myocyte progenitor cells are autologous. 11. The pharmaceutical composition of claim 1, wherein said vascular progenitor cells do not express cardiac lineage markers GATA6, Ets1, Tie-2, VE-cadherin, CD62E/E-selectin, alpha-SM-actin, CD31 (PECAM-1), vWF, Bandeiraera simplicifolia lectins, Ulex europaeus lectins, GATA4, Nkx2.5, MEF2C, or alpha-sarcomeric actin. 12. The pharmaceutical composition of claim 5, wherein said myocyte progenitor cells do not express cardiac lineage markers GATA6, Ets1, Tie-2, VE-cadherin, CD62E/E-selectin, alpha-SM-actin, CD31 (PECAM-1), vWF, Bandeiraera simplicifolia lectins, Ulex europaeus lectins, GATA4, Nkx2.5, MEF2C, or alpha-sarcomeric actin. 13. The pharmaceutical composition of claim 7, wherein said cardiomyocytes generated from said myocyte progenitor cells have the electrical, mechanical and calcium transient properties of mature myocytes. 14. A pharmaceutical composition comprising isolated adult vascular progenitor cells, isolated adult myocyte progenitor cells, and a pharmaceutically acceptable carrier, wherein the vascular progenitor cells are lineage negative, c-kit positive, VEGFR-2 positive, wherein the myocyte progenitor cells are lineage negative, c-kit positive, and VEGFR-2 negative, and wherein the ratio of vascular progenitor cells to myocyte progenitor cells is about 1:20, 1:10, 1:5, 1:2, 1:1, 2:1, 5:1, 10:1, or 20:1. 15. The pharmaceutical composition of claim 14, wherein the ratio of vascular progenitor cells to myocyte progenitor cells is about 1:1. 16. The pharmaceutical composition of claim 14, wherein said vascular progenitor cells and said myocyte progenitor cells are human. 17. The pharmaceutical composition of claim 1 or claim 5, wherein the pharmaceutically acceptable carrier is sterile water, physiological saline, or glucose. 18. The pharmaceutical composition of claim 1 or claim 5, wherein the composition is isotonic.

Details for Patent 8,119,123

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2027-11-30